Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EXPEDITED APPROVAL LEGISLATION SUPPORTED BY KEY REPUBLICANS

Executive Summary

EXPEDITED APPROVAL LEGISLATION SUPPORTED BY KEY REPUBLICANS, but Democrat health legislators are questioning the need for such a bill. Rep. Bliley (R-Va.), ranking minority member of the House Energy & Commerce/Oversight Subcommittee, said he is working with other legislators on an expedited approval bill. Bliley told a June 12 Health Subcommittee hearing on the Edwards Advisory Committee to FDA (see related story, p. 5) that he is "working with others to draft legislation that will speed up the drug approval process at the FDA for any drug with patients in danger." The Virginia Republican urged his colleagues to support the effort "so that we can fight the barriers and inefficiencies of the FDA drug approval process." However, key Democrats on the Energy & Commerce Committee are not supportive of such legislation. Committee Chairman Dingell (D- Mich.) reportedly believes there is no need for statutory changes because FDA can speed the approval process administratively, as it has for AIDS and cancer drug reviews. Health Subcommittee Chairman Waxman (D-Calif.) is said to oppose legislation that would relax safety and efficacy standards for approval. The idea for legislation directed at expediting FDA approvals derives from the debate over conditional approval. However, that terminology has been rejected on the Hill because it indicates that an approval is not final. During a Senate hearing on the Edwards Committee report, Sen. Hatch (R-Utah) announced his intention to pursue expedited approval legislation ("The Pink Sheet" May 20, p. 9). The ranking Republican on the Labor & Human Resources Committee requested the help of former staffer Lawrence Horowitz, MD, a member of the Edwards Committee, which recommended that FDA approve drugs with less rigorous standards for desperately ill patients willing to assume greater risk. However, Labor & Human Resources Committee Chairman Kennedy (D-Mass.) reportedly believes that FDA can decide to expedite approvals for such circumstances by pursuing an administrative route.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS019321

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel